Does the media favor EYPT or LAB?

In the previous week, Standard BioTools had 3 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 5 mentions for Standard BioTools and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 1.87 beat Standard BioTools' score of 0.58 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, LAB or TRNS?

Transcat has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Standard BioTools $85.33M 4.05 -$74.90M $0.20 4.43 Transcat $331.88M 2.53 $5.38M $0.58 155.17

Does the media prefer LAB or TRNS?

In the previous week, Standard BioTools had 3 more articles in the media than Transcat. MarketBeat recorded 5 mentions for Standard BioTools and 2 mentions for Transcat. Transcat's average media sentiment score of 0.85 beat Standard BioTools' score of 0.58 indicating that Transcat is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Transcat 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CTKB or LAB?

In the previous week, Standard BioTools had 3 more articles in the media than Cytek Biosciences. MarketBeat recorded 5 mentions for Standard BioTools and 2 mentions for Cytek Biosciences. Standard BioTools' average media sentiment score of 0.58 beat Cytek Biosciences' score of 0.30 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer OPTX or LAB?

Standard BioTools has a consensus price target of $1.35, suggesting a potential upside of 52.34%. Given Standard BioTools' stronger consensus rating and higher possible upside, analysts clearly believe Standard BioTools is more favorable than Syntec Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syntec Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Standard BioTools 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media favor OPTX or LAB?

In the previous week, Syntec Optics had 1 more articles in the media than Standard BioTools. MarketBeat recorded 6 mentions for Syntec Optics and 5 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.58 beat Syntec Optics' score of 0.35 indicating that Standard BioTools is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Syntec Optics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Standard BioTools 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Standard BioTools (LAB) Competitors

$0.89 +0.08 (+10.33%)

Closing price 04:00 PM Eastern

Extended Trading

$0.88 -0.01 (-0.70%)

As of 08:00 PM Eastern

Compare

LAB vs. EYPT, TRNS, FEIM, CTKB, and OPTX

Should you buy Standard BioTools stock or one of its competitors? MarketBeat compares Standard BioTools with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Standard BioTools include Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Frequency Electronics (FEIM), Cytek Biosciences (CTKB), and Syntec Optics (OPTX). These companies are all part of the "measuring and control equipment" industry.

How does Standard BioTools compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 26.8% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Standard BioTools had 3 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 5 mentions for Standard BioTools and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 1.87 beat Standard BioTools' score of 0.58 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eyepoint Pharmaceuticals has a beta of 1.72, suggesting that its stock price is 72% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Standard BioTools has a net margin of 73.46% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Standard BioTools' return on equity of -8.18% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Standard BioTools	73.46%	-8.18%	-6.43%

Eyepoint Pharmaceuticals presently has a consensus target price of $31.80, indicating a potential upside of 170.18%. Standard BioTools has a consensus target price of $1.35, indicating a potential upside of 52.34%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Standard BioTools has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	31.46	-$231.96M	-$3.50	N/A
Standard BioTools	$85.33M	4.05	-$74.90M	$0.20	4.43

Summary

Standard BioTools beats Eyepoint Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Standard BioTools compare to Transcat?

Standard BioTools (NASDAQ:LAB) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Standard BioTools had 3 more articles in the media than Transcat. MarketBeat recorded 5 mentions for Standard BioTools and 2 mentions for Transcat. Transcat's average media sentiment score of 0.85 beat Standard BioTools' score of 0.58 indicating that Transcat is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Transcat	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Standard BioTools has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Transcat has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market.

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 98.3% of Transcat shares are held by institutional investors. 26.8% of Standard BioTools shares are held by insiders. Comparatively, 2.8% of Transcat shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Standard BioTools presently has a consensus price target of $1.35, suggesting a potential upside of 52.34%. Transcat has a consensus price target of $105.33, suggesting a potential upside of 17.04%. Given Standard BioTools' higher possible upside, equities research analysts clearly believe Standard BioTools is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Transcat has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	4.05	-$74.90M	$0.20	4.43
Transcat	$331.88M	2.53	$5.38M	$0.58	155.17

Standard BioTools has a net margin of 73.46% compared to Transcat's net margin of 1.62%. Transcat's return on equity of 5.84% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	73.46%	-8.18%	-6.43%
Transcat	1.62%	5.84%	3.78%

Summary

Transcat beats Standard BioTools on 11 of the 17 factors compared between the two stocks.

How does Standard BioTools compare to Frequency Electronics?

Frequency Electronics (NASDAQ:FEIM) and Standard BioTools (NASDAQ:LAB) are both small-cap measuring and control equipment companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Frequency Electronics has higher earnings, but lower revenue than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Frequency Electronics	$69.81M	9.44	$23.69M	$0.75	89.25
Standard BioTools	$85.33M	4.05	-$74.90M	$0.20	4.43

Frequency Electronics presently has a consensus price target of $43.67, suggesting a potential downside of 34.77%. Standard BioTools has a consensus price target of $1.35, suggesting a potential upside of 52.34%. Given Standard BioTools' higher possible upside, analysts plainly believe Standard BioTools is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

58.6% of Frequency Electronics shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 28.0% of Frequency Electronics shares are held by company insiders. Comparatively, 26.8% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Standard BioTools had 4 more articles in the media than Frequency Electronics. MarketBeat recorded 5 mentions for Standard BioTools and 1 mentions for Frequency Electronics. Frequency Electronics' average media sentiment score of 0.93 beat Standard BioTools' score of 0.58 indicating that Frequency Electronics is being referred to more favorably in the media.

Company	Overall Sentiment
Frequency Electronics	Positive
Standard BioTools	Positive

Frequency Electronics has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Standard BioTools has a net margin of 73.46% compared to Frequency Electronics' net margin of 10.78%. Frequency Electronics' return on equity of 12.69% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Frequency Electronics	10.78%	12.69%	7.84%
Standard BioTools	73.46%	-8.18%	-6.43%

Summary

Frequency Electronics beats Standard BioTools on 12 of the 17 factors compared between the two stocks.

How does Standard BioTools compare to Cytek Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Cytek Biosciences has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

Cytek Biosciences currently has a consensus price target of $5.69, indicating a potential upside of 37.71%. Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 52.34%. Given Standard BioTools' higher possible upside, analysts clearly believe Standard BioTools is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Standard BioTools has a net margin of 73.46% compared to Cytek Biosciences' net margin of -36.25%. Standard BioTools' return on equity of -8.18% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Standard BioTools	73.46%	-8.18%	-6.43%

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Comparatively, 26.8% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cytek Biosciences has higher revenue and earnings than Standard BioTools. Cytek Biosciences is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.65	-$66.54M	-$0.57	N/A
Standard BioTools	$85.33M	4.05	-$74.90M	$0.20	4.43

In the previous week, Standard BioTools had 3 more articles in the media than Cytek Biosciences. MarketBeat recorded 5 mentions for Standard BioTools and 2 mentions for Cytek Biosciences. Standard BioTools' average media sentiment score of 0.58 beat Cytek Biosciences' score of 0.30 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Standard BioTools beats Cytek Biosciences on 11 of the 16 factors compared between the two stocks.

How does Standard BioTools compare to Syntec Optics?

Syntec Optics (NASDAQ:OPTX) and Standard BioTools (NASDAQ:LAB) are both small-cap measuring and control equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Syntec Optics has higher earnings, but lower revenue than Standard BioTools. Syntec Optics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syntec Optics	$28.08M	16.68	-$1.79M	-$0.08	N/A
Standard BioTools	$85.33M	4.05	-$74.90M	$0.20	4.43

Syntec Optics has a beta of -0.82, meaning that its stock price is 182% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

53.7% of Standard BioTools shares are held by institutional investors. 0.8% of Syntec Optics shares are held by insiders. Comparatively, 26.8% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Standard BioTools has a net margin of 73.46% compared to Syntec Optics' net margin of -10.95%. Standard BioTools' return on equity of -8.18% beat Syntec Optics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syntec Optics	-10.95%	-30.86%	-12.35%
Standard BioTools	73.46%	-8.18%	-6.43%

In the previous week, Syntec Optics had 1 more articles in the media than Standard BioTools. MarketBeat recorded 6 mentions for Syntec Optics and 5 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.58 beat Syntec Optics' score of 0.35 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syntec Optics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Standard BioTools	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Standard BioTools has a consensus price target of $1.35, suggesting a potential upside of 52.34%. Given Standard BioTools' stronger consensus rating and higher possible upside, analysts clearly believe Standard BioTools is more favorable than Syntec Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syntec Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Standard BioTools beats Syntec Optics on 12 of the 15 factors compared between the two stocks.

Get Standard BioTools News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LAB vs. The Competition

Export

Metric	Standard BioTools	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$313.54M	$1.52B	$6.64B	$12.06B
Dividend Yield	N/A	N/A	2.67%	5.55%
P/E Ratio	4.43	50.61	20.93	22.06
Price / Sales	4.05	6.98	508.64	105.22
Price / Cash	N/A	22.77	42.36	56.09
Price / Book	0.81	4.85	10.47	6.72
Net Income	-$74.90M	-$54.76M	$3.56B	$337.35M
7 Day Performance	-23.60%	-4.88%	-1.11%	-2.54%
1 Month Performance	-13.12%	1.17%	1.28%	1.42%
1 Year Performance	-17.94%	-10.58%	21.20%	24.71%

Standard BioTools Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LAB Standard BioTools	2.7526 of 5 stars	$0.89 +10.3%	$1.35 +52.3%	-24.2%	$313.54M	$85.33M	4.43	620	News Coverage High Trading Volume
EYPT Eyepoint Pharmaceuticals	3.198 of 5 stars	$11.57 +1.1%	$31.80 +174.8%	+28.1%	$970.63M	$7.61M	N/A	120
TRNS Transcat	2.9323 of 5 stars	$90.94 +1.3%	$105.33 +15.8%	+15.1%	$849.33M	$331.88M	156.79	1,413
FEIM Frequency Electronics	1.3985 of 5 stars	$69.69 -0.4%	$43.67 -37.3%	+266.1%	$685.75M	$69.81M	92.92	200
CTKB Cytek Biosciences	2.1265 of 5 stars	$4.05 +0.1%	$5.69 +40.6%	+17.4%	$523.68M	$204.17M	N/A	500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LAB) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Standard BioTools (LAB) Competitors

LAB vs. EYPT, TRNS, FEIM, CTKB, and OPTX

How does Standard BioTools compare to Eyepoint Pharmaceuticals?

Summary

How does Standard BioTools compare to Transcat?

Summary

How does Standard BioTools compare to Frequency Electronics?

Summary

How does Standard BioTools compare to Cytek Biosciences?

Summary

How does Standard BioTools compare to Syntec Optics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Standard BioTools (LAB) Competitors

LAB vs. EYPT, TRNS, FEIM, CTKB, and OPTX

How does Standard BioTools compare to Eyepoint Pharmaceuticals?

Do institutionals & insiders believe in EYPT or LAB?

Does the media favor EYPT or LAB?

Which has more risk and volatility, EYPT or LAB?

Is EYPT or LAB more profitable?

Do analysts recommend EYPT or LAB?

Which has preferable earnings and valuation, EYPT or LAB?

Summary

How does Standard BioTools compare to Transcat?

Does the media prefer LAB or TRNS?

Which has more volatility & risk, LAB or TRNS?

Do insiders & institutionals hold more shares of LAB or TRNS?

Do analysts rate LAB or TRNS?

Which has preferable valuation & earnings, LAB or TRNS?

Is LAB or TRNS more profitable?

Summary

How does Standard BioTools compare to Frequency Electronics?

Which has stronger valuation & earnings, FEIM or LAB?

Do analysts prefer FEIM or LAB?

Do insiders and institutionals have more ownership in FEIM or LAB?

Does the media refer more to FEIM or LAB?

Which has more risk & volatility, FEIM or LAB?

Is FEIM or LAB more profitable?

Summary

How does Standard BioTools compare to Cytek Biosciences?

Which has more risk and volatility, CTKB or LAB?

Do analysts prefer CTKB or LAB?

Is CTKB or LAB more profitable?

Do insiders & institutionals have more ownership in CTKB or LAB?

Which has higher valuation & earnings, CTKB or LAB?

Does the media favor CTKB or LAB?

Summary

How does Standard BioTools compare to Syntec Optics?

Which has better earnings and valuation, OPTX or LAB?

Which has more risk & volatility, OPTX or LAB?

Do insiders and institutionals have more ownership in OPTX or LAB?

Is OPTX or LAB more profitable?

Does the media favor OPTX or LAB?

Do analysts prefer OPTX or LAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools